Welcome, Guest. Please login or register.
April 18, 2024, 03:47:19 am

Login with username, password and session length

  • Total Members: 6307
  • Latest: golfer
  • Total Posts: 55125
  • Total Topics: 4851
  • Online Today: 60
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 46
Total: 46


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Is NASH the next Hepatitis C?  (Read 6547 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Is NASH the next Hepatitis C?
« on: January 28, 2015, 11:15:50 am »
Gilead Sciences, maker of hepatitis C virus (HCV) drugs Sovaldi and Harvoni, is now eyeing a new liver disease on the rise: nonalcoholic steatohepatitis, or NASH. And it just paid as much as $470 million to corner the market.

Closely related to obesity, NASH is a chronic hepatic condition characterized by excessive fat and inflammation in the liver. The condition, an advanced form of fatty liver disease, can lead to cirrhosis, fibrosis and eventually liver failure—kind of like hep C.

But NASH is far more common than the HCV virus: The disease is expected to affect as many as half of all Americans by 2030.

Read more: http://www.hepmag.com/articles/gilead_phenex_nash_buyout_2831_26734.shtml
« Last Edit: January 28, 2015, 11:18:01 am by Hep Editors »

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Re: Is NASH the next Hepatitis C?
« Reply #1 on: January 28, 2015, 11:16:26 am »


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.